Pushing the boundaries
At Kodiak, we are working to develop disruptive products and platforms to prevent and treat the leading causes of blindness
Same Where It Matters
Different Where It Counts
In general, the larger the size, the longer the molecule will remain in the eye.
Drug per dose is how many target binding units fit into the injected clinical dose.
Ocular half-life is how long the drug lasts in the eye which is a key driver of durability.
Remarkable Intraocular Half-life
Medicines built on the ABC Platform (e.g., KSI-301) last longer and better maintain therapeutic concentration levels in the eye
Excellent Retinal Bioavailability
The ABC Platform improves therapeutic absorption and distribution in the eye
Deeper Inhibitory Potency
The ABC Platform binds and inhibits VEGF in a more relevant way
Fast Systemic Clearing
The ABC Platform is designed to clear the body quickly after it exits from the eye
Some of the statements on this site are forward-looking. Such statements are inherently subject to known as well as unknown risks and uncertainties, including scientific, business, economic and financial factors and other factors that may cause actual results, performance or achievements of Kodiak Sciences to be materially different from those expected or anticipated in the forward-looking statements. Forward-looking statements speak only as of the date they are posted to this website (unless an earlier date is indicated). Kodiak Sciences does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. Kodiak’s drug candidates are investigational compounds in development and have not received regulatory approval in any country.